Guided Therapeutics, Inc. (OTCMKTS:GTHP – Get Free Report) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totalling 13,100 shares, an increase of 36.5% from the September 15th total of 9,600 shares. Based on an average daily trading volume, of 9,100 shares, the days-to-cover ratio is presently 1.4 days.
Guided Therapeutics Stock Performance
Guided Therapeutics stock opened at $0.14 on Tuesday. Guided Therapeutics has a 1 year low of $0.06 and a 1 year high of $0.25. The firm has a 50 day moving average price of $0.14 and a 200 day moving average price of $0.12. The company has a market cap of $8.46 million, a price-to-earnings ratio of -4.67 and a beta of 0.52.
Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.01) EPS for the quarter.
About Guided Therapeutics
Guided Therapeutics, Inc, a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light.
Further Reading
- Five stocks we like better than Guided Therapeutics
- What is a Special Dividend?
- The S&P 500 Defies Odds, Extends Rally With 6,000 in Sight
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Big Potential Brewing – Will Walgreens Deliver a Rally?
- What Do S&P 500 Stocks Tell Investors About the Market?
- CVS Health: Are Its Parts Worth More Than the Whole?
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
